抗CD20抗体によるB細胞リンパ腫の治療 Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies.:Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies

この論文にアクセスする

この論文をさがす

著者

抄録

The CD 20 antigen is expressed consistently on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric IgG 1 kappa monoclonal antibody (mAb) with mouse variable and human constant regions that recognizes the CD 20 antigen. <I>In vitro</I> experiments have revealed that rituximab lyses human B-cells through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. The toxicities of rituximab are mainly non-hematological grade 1 or 2 episodes. Hematological toxicities are not severe. In the phase I/II study in the USA, an overall response rate (ORR) of 50% was obtained in relapsed low-grade B-cell lymphoma. The median time to progression (TTP) of the responders was 10.2 months. The good response rate and fairly long TTP were reproduced in a subsequent pivotal trial, which enrolled 166 patients with low-grade or follicular B-cell lymphoma. In the phase I study in Japan, 12 patients with relapsed CD 20<SUP>+</SUP>B-cell lymphoma were enrolled : 4 at 250 mg/m<SUP>2</SUP> and 8 at 375 mg/m<SUP>2</SUP>, once a week for 4 weeks. Of the 11 eligible pts, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m<SUP>2</SUP> × 4 weekly infusions. The ORR in indolent B-dell lymphoma and MCL were 61% (37/61) and 46% (6/13), respectively. Several trials of rituximab in combination with chemotherapy have revealed promising results not only for indolent B-cell lymphoma but also for aggressive B-cell lymphoma. Particularly, rituximab plus CHOP therapy might become a new standard regimen for untreated aggressive B-cell lymphoma.

収録刊行物

  • Drug delivery system

    Drug delivery system 17(1), 35-41, 2002-01-10

    日本DDS学会

参考文献:  25件中 1-25件 を表示

各種コード

  • NII論文ID(NAID)
    10008132011
  • NII書誌ID(NCID)
    AN10084591
  • 本文言語コード
    JPN
  • 資料種別
    REV
  • ISSN
    09135006
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ